Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital

Executive Summary

• Ocumetics Technology Corp. closed the first tranche of its best‑efforts brokered private placement and a concurrent non‑brokered private placement, raising approximately $1.02 million in gross proceeds.
• The offering consisted of 1,706,383 Units sold at $0.60 per Unit, each Unit containing one common share and one warrant to purchase an additional share at $0.75 until 30 Dec 2028.
• Proceeds are earmarked for the company’s first‑in‑human clinical trials, ongoing R&D, and general corporate purposes.

Key Details

• Total Gross Proceeds: ~$1,023,830 (Brokered: $788,380; Non‑brokered: $235,450).
• Units Sold: 1,706,383 Units at $0.60 per Unit.
• Unit Composition: 1 common share + 1 Common Share purchase warrant.
• Warrant Terms: Right to purchase one additional common share at $0.75 per share, exercisable until 30 Dec 2028.
• Lead Agent / Bookrunner: Centurion One Capital Corp. (also fiscal advisor for the non‑brokered portion).
• Legal Counsel: Tingle Merrett LLP (company), Cassels Brock & Blackwell LLP (lead agent).
• Commission & Fees Paid: $143,336.17 total; $61,429.79 paid via issuance of 102,382 Units and 136,510 warrants issued.
• Use of Proceeds: Funding first‑in‑human clinical trials, ongoing research & development, and general corporate purposes (subject to change).
• Regulatory Exemptions: Offered under the Listed Issuer Financing Exemption (NI 45‑106) in Canada and applicable U.S. securities exemptions; no statutory hold period in Canada.
• Related Party Transaction: Approved unanimously by directors; relied on MI 61‑101 exemptions for minority shareholder approval and valuation requirements.

Notable Quotes

(No direct quotes were provided in the release.)